Ubrelvy generic
Ubrelvy is a prescription medication owned by Abbvie Inc. The drug contains the active ingredient ubrogepant and is available in tablet form for oral administration. Its primary use is for the acute treatment of migraine with or without aura in adults, including those with severe hepatic impairment. Ubrelvy was initially authorized for market use on December 23, 2019, and currently holds 6 drug patents, none of which have expired yet.
When will Ubrelvy generic be available?
None of the drug patents of Ubrelvy have expired as of yet. The last patent is due to expire on December 22, 2041, potentially resulting in the availability of Ubrelvy generics by this date. However, drug patent challenges against Ubrelvy can be initiated from December 24, 2023.
Ubrelvy uses
Ubrelvy provides effective relief by targeting and blocking calcitonin gene-related peptide (CGRP) receptors, which are believed to play a crucial role in migraine attacks. The active ingredient in Ubrelvy, ubrogepant, is a CGRP receptor antagonist, intervening in the transmission of migraine pain signals and alleviating symptoms.
Ubrelvy patent expiration
Ubrelvy's patents cover multiple aspects of the drug, including its formulation and use in migraine treatment. The final patent, which pertains to the treatment of migraine, is set to expire on December 22, 2041. Until then, the manufacture and sale of Ubrelvy generic is anticipated to be unlikely. Below is the detail of the patent: